Kailera Therapeutics, Inc. (KLRA) stock
KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
Kailera Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $84.67M | +333.7% |
| Q2 FY2026 | Jun 30, 2026 | $101.06M | +897.6% |
| Q1 FY2026 | Mar 31, 2026 | $70.87M | – |
| Q3 FY2025 | Sep 30, 2025 | $26.99M | – |
| Q2 FY2025 | Jun 30, 2025 | $19.52M | – |
| Q1 FY2025 | Mar 31, 2025 | $10.13M | – |
See a number that looks wrong?